Immunicum’s ilixadencel successful in kidney cancer
The drug achieved complete tumour responses in five out of 45 metastatic kidney cancer patients, compared to one in 25.
Read More
Tag: sunitinib
Keytruda combo wins FDA approval for RCC
The approval is based on results of the KEYNOTE-426 study, in which Keytruda in combination with Inlyta was found to reduce the risk of death by nearly half compared to Sutent.
Read More
NICE appraisal for BMS kidney cancer immunotherapy combination
The Institute gave a positive FAD to the Opdivo and Yervoy combination in renal cell carcinoma, approving funding via the Cancer Drugs Fund.
Read More
Keytruda/Inlyta combo shows significant survival benefit in kidney cancer trial
A pivotal Phase III trial investigating a combination of MSD’s anti-PD-1 therapy Keytruda and Pfizer’s tyrosine kinase inhibitor Inlyta has shown a significant benefit on both overall (OS) and progression-free survival (PFS) in patients with kidney cancer.
Read More
BMS’ Opdivo/Yervoy combo cleared for kidney cancer
US regulators have approved a combination of Bristol-Myers Squibb’s immunotherapy drugs Opdivo and Yervoy as a first-line treatment for patients with advanced renal cell carcinoma.
Read More
FDA widens scope of Pfizer’s Sutent in kidney cancer
The US Food and Drug Administration has cleared Pfizer’s Sutent for adjuvant treatment of adults at a high risk of their kidney cancer returning after a kidney has been removed.
Read More
Mixed results for BMS’ Opdivo, Yervoy combo in kidney cancer
A combination of Bristol-Myers Squibb’s Opdivo and Yervoy has failed to significantly improve progression-free survival (PFS) compared to Pfizer’s Sutent in patients with renal cancer.
Read More
NICE backs Afinitor, Sutent for neuroendocrine tumours
Novartis’ Afinitor and Pfizer’s Sutent have received backing from the National Institute for Health and Care Excellence as cost-effective treatment options for certain neuroendocrine tumours (NETs).
Read More
Data backs broader use of Pfizer’s Sutent in kidney cancer
A Phase III study pitting adjuvant use of Pfizer’s Sutent against a placebo in patients with kidney cancer has met its primary endpoint of showing improved disease-free survival (DFS) in those taking the drug.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
